2023
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Bhagchandani S, Vohidov F, Milling L, Tong E, Brown C, Ramseier M, Liu B, Fessenden T, Nguyen H, Kiel G, Won L, Langer R, Spranger S, Shalek A, Irvine D, Johnson J. Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Science Advances 2023, 9: eadg2239. PMID: 37075115, PMCID: PMC10115420, DOI: 10.1126/sciadv.adg2239.Peer-Reviewed Original ResearchConceptsToll-like receptor 7Cancer immunotherapyImmune stimulationMouse syngeneic tumor modelsNext-generation cancer immunotherapyImmune-related toxicitiesAcute systemic inflammationInnate immune cellsSyngeneic tumor modelsPotential cancer immunotherapySystemic inflammationImmune cellsReceptor 7Systemic administrationIntravenous administrationMyeloid cellsTumor growthSystemic toxicityTumor modelObservable systemic toxicityPotent stimulationImidazoquinolinesImmunotherapyStimulationProdrug
2021
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Bhagchandani S, Johnson J, Irvine D. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Advanced Drug Delivery Reviews 2021, 175: 113803. PMID: 34058283, PMCID: PMC9003539, DOI: 10.1016/j.addr.2021.05.013.Peer-Reviewed Original ResearchConceptsVaccine adjuvantsImidazoquinoline derivativesToll-like receptor 7Candidate vaccine adjuvantsSkin cancer treatmentBroad therapeutic utilityTLR7 toleranceTopical antiviralsImmunomodulatory agentsReceptor 7Systemic administrationPoor pharmacokinetic propertiesTherapeutic utilitySuccessful clinical translationSynthetic agonistsAntiviral formulationsInfectious diseasesPharmacokinetic propertiesCancer treatmentBroad expression profileAdjuvantClinical translationBiodistributionExpression profilesTherapeutics